Adaptive Biotechnologies Balance Sheet Health
Financial Health criteria checks 5/6
Adaptive Biotechnologies has a total shareholder equity of $223.6M and total debt of $132.7M, which brings its debt-to-equity ratio to 59.4%. Its total assets and total liabilities are $558.5M and $334.9M respectively.
Key information
59.4%
Debt to equity ratio
US$132.70m
Debt
| Interest coverage ratio | n/a |
| Cash | US$243.33m |
| Equity | US$223.57m |
| Total liabilities | US$334.93m |
| Total assets | US$558.51m |
Recent financial health updates
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Recent updates
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09Financial Position Analysis
Short Term Liabilities: ADPT's short term assets ($308.3M) exceed its short term liabilities ($87.6M).
Long Term Liabilities: ADPT's short term assets ($308.3M) exceed its long term liabilities ($247.3M).
Debt to Equity History and Analysis
Debt Level: ADPT has more cash than its total debt.
Reducing Debt: ADPT's debt to equity ratio has increased from 0% to 59.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADPT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ADPT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 29.6% each year